Iomeprol
Clinical data
Trade namesImeron, Iomeron
Routes of
administration		Intravenous, by mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Metabolismnone
Elimination half-life109±20 min
Excretionvia kidneys
Identifiers
  • 1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H22I3N3O8
Molar mass777.089 g·mol−1
3D model (JSmol)
  • Ic1c(c(I)c(c(I)c1N(C(=O)CO)C)C(=O)NCC(O)CO)C(=O)NCC(O)CO
  • InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
  • Key:NJKDOADNQSYQEV-UHFFFAOYSA-N

Iomeprol is a pharmaceutical drug used as a radiocontrast agent in X-ray imaging. It is sold under the trade names Imeron and Iomeron.[1][2]

It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium.[1] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents.[1]

The substance is not metabolized in the human body but excreted in unchanged form. It is decomposed slowly and can therefore accumulate in the environment.[3]

See also

References

  1. 1 2 3 Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group of the South African Medical Association. ISBN 978-1-875098-30-9. OCLC 869772940.
  2. ↑ Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.
  3. ↑ Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, Steinbach A, Flottmann D (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.